Filing Details

Accession Number:
0001209191-19-020763
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-21 16:37:57
Reporting Period:
2019-03-20
Accepted Time:
2019-03-21 16:37:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1328143 Adamas Pharmaceuticals Inc ADMS Pharmaceutical Preparations (2834) 421560076
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1604541 T Gregory Went C/O Adamas Pharmaceuticals, Inc.
1900 Powell St., Suite 1000
Emeryville CA 94608
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-03-20 6,319 $7.99 176,291 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 199,242 Indirect By Trust
Footnotes
  1. Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
  2. The shares were sold at prices ranging from $7.94 to $8.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.